Author(s)

Chatté Adawaye, Kamangu Erick, Soudy I. Djibrine, Aoudalkarim Moussa Chahad, Ali Mahamat Moussa, Tchombou HZ Bertin, Vaira Dolores, Moutschen Michel

Department of Basic Sciences, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of Congo.
Faculty of Health Sciences, National Reference General Hospital, Ndjamena, Chad.
Institute University of Sciences and Technology of Abeche, Abeche, Chad.
Laboratoire AIDS Reference, CHU Liège, Liège, Belgium.
Service Infectious Diseases and General Internal Medicine, CHU Liège, Liège, Belgium.

Contexte: The fight against HIV/AIDS epidemics is one of the greatest challenges of this century. The epidemic affects generally under-developed countries, and Sub-Saharan Africa are the most concerned. The combined marketed form known as Triomune was used as first-line treatment in several sub-Saharan African Countries (60% of VIH infected people), including Chad. However, no evaluation has been done for that treatment in the country. Objective: To evaluate the efficacy and safety immuno-virological of Triomune at the General Hospital in N’Djamena/Chad. Methods: 48 HIV-1 positive patients eligible for ARV treatment were enrolled in our study, and they have been then followed for 8 months. We have measured in these patients the CD4 cell count before treatment and at the 8th month of treatment. After 8 months of treatment, we have also evaluated the Lymphocyte T CD4 and the plasma viral load (VL). Comparisons of means of CD4 lymphocytes and plasma CV (≥1000 copies/ml) were used to define treatment failure. Results: 48 patients were under Triomune regime. The average CD4 count was decreased from 462 ± 179.22 [56 - 981] cells/mm³ before treatment to 327.23 ± 153.77 [10 - 1008] cells/mm³ at the 8th month of treatment. The mean plasma viral load for patients was 66008.62 copies/ml. The failure rate to Triomune was 43.75% (21/48). Conclusion: Aside from the side effects already described for Triomune, our study reveals a high treatment failure rate. Hence, there is the need of regular revisions of therapeutic regime administer in the first intention.

Plasma, Viral Load, Triomune, Antiretroviral Therapy, Virological Failure, ARVs, HIV-1, First Line

Adawaye, C. , Erick, K. , Djibrine, S. , Chahad, A. , Moussa, A. , Bertin, T. , Dolores, V. and Michel, M. (2014) Immunovirologic Evaluation of Triomune (Lamivudine, Stavudine and Nevirapine) Antiretroviral Therapy in First Line HIV-1 Adult Patients in N’Djamena, Chad. World Journal of AIDS, 4, 301-305. doi: 10.4236/wja.2014.43035.